Trevi Therapeutics, Inc. TRVI
13.86 USD +0.23 (+1.69%)
At closeNov 3, 2026, 4:01 PM EST
13.86 0.00 0.00%
After hours · Nov 3, 4:01 PM ET
13.74 Day range 14.23
9.82 52-week range 20.22
- YTD
- +10.70%
- 1 year
- +29.53%
- Market cap
- 1.97B
- EPS (ttm)
- -0.35
- Shares out
- 142.48M
- Forward P/E
- -24.02
- YTD return
- +10.70%
- 1-year return
- +29.53%
- Volume
- 1.18M
- Avg volume
- 1.96M
- Open
- 13.81
- Previous close
- 13.63
- Day's range
- 13.74 – 14.23
- 52-week range
- 9.82 – 20.22
- Beta
- 1.12
- Price target
- 28.18 (+103.3%)
- Earnings date
- Nov 12, 2026
2Y +10.83 (+356.25%)
Key statistics
- Enterprise value
- 1.62B
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 6.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -33.28M
- Total cash
- 318.87M
- Total debt
- 605.00K
- Return on equity
- -19.66%
- Short % of float
- 12.47%
- 50-day average
- 14.61
- 200-day average
- 14.36
Analyst view
Price target (mean) 28.18 +103.3% upside
Now 13.86
- Target (low)
- 23.00
- Target (mean)
- 28.18
- Target (high)
- 40.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy2
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 12, 2026
Expected Nov 12, 2026. Consensus EPS estimate -0.133.
Financials — quick view
TRVI Revenue — quarterly 0
TRVI Net income — quarterly -17.80M
TRVI EPS — quarterly -0.11
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2026 | Sep 30, 2026 | -0.13167 | — | — | — |
| Aug 6, 2026 | Jun 30, 2026 | -0.10946 | -0.11 | 0.00 | -0.49% |
| May 5, 2026 | Mar 31, 2026 | -0.07 | -0.09 | -0.02 | -28.57% |
| Mar 17, 2026 | Dec 31, 2025 | -0.10 | -0.06 | +0.04 | +40.00% |
| Nov 13, 2025 | Sep 30, 2025 | -0.10 | -0.08 | +0.02 | +20.00% |
| Aug 7, 2025 | Jun 30, 2025 | -0.10 | -0.09 | +0.01 | +10.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 2026 | Jones Trading | main | Buy | Buy |
| Aug 7, 2026 | Oppenheimer | main | Outperform | Outperform |
| Aug 7, 2026 | Cantor Fitzgerald | main | Overweight | Overweight |
| Jul 21, 2026 | BMO Capital | init | Outperform | Outperform |
| Jul 20, 2026 | B. Riley Securities | main | Buy | Buy |
| Jul 20, 2026 | HC Wainwright & Co. | main | Buy | Buy |
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough. Trevi Therapeutics, Inc. has a license agreement with Keenova Therapeutics plc to develop and commercialize products incorporating nalbuphine hydrochloride in various formulations. Trevi Therapeutics, Inc. was incorporated in 2011 and is headquartered in New Haven, Connecticut.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- trevitherapeutics.com
News
Trevi Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 9, 2026 
Trevi Therapeutics to Participate in Stifel's 2026 Healthcare Conference 
Trevi Therapeutics Announces Results From Phase 2b CORAL Trial Accepted As Oral Presentation At CHEST 2026 Annual Meeting Of American College Of Chest Physicians 
Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual Meeting 
Trevi Therapeutics Q2 2026 Earnings Call Transcript 
Trevi Therapeutics, Inc. (TRVI) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript 
Trevi Therapeutics to Participate in Upcoming September Conferences 
Trevi Therapeutics Announces Upcoming Presentations at the European Respiratory Society (ERS) Congress 2026 
Trevi Therapeutics: A Specialty Beachhead Creates A Chronic Cough Platform 
Jones Trading Maintains Buy on Trevi Therapeutics, Raises Price Target to $28
Your note
Sign in to keep a note on TRVI — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BASKETT FOREST | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 16, 2025 | 0 |
| BEHBAHANI ALI | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 16, 2025 | 0 |
| CHANG CARMEN | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 16, 2025 | 0 |
| FLORENCE ANTHONY A JR | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 16, 2025 | 0 |
| GOOD JENNIFER L | Chief Executive Officer | Sale | Mar 20, 2025 | 213,313 |
| MAKHZOUMI MOHAMAD | Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Apr 16, 2025 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| NEA Management Company, LLC | 9.28% | 13,222,228 | 183.26M | Jun 29, 2026 |
| FMR, LLC | 8.82% | 12,562,839 | 174.12M | Jun 29, 2026 |
| Blackrock Inc. | 7.83% | 11,155,026 | 154.61M | Jun 29, 2026 |
| Frazier Life Sciences Management, L.P. | 6.98% | 9,939,447 | 137.76M | Jun 29, 2026 |
| Wellington Management Group, LLP | 3.99% | 5,684,592 | 78.79M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 3.88% | 5,530,675 | 76.66M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.84% | 4,047,125 | 56.09M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 1.98% | 2,819,880 | 39.08M | Sep 29, 2026 |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.87% | 2,660,000 | 36.87M | Jun 29, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 1.67% | 2,374,785 | 32.91M | Aug 30, 2026 |
| Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.37% | 1,950,341 | 27.03M | Jul 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.95% | 1,353,312 | 18.76M | Jun 29, 2026 |